Compare GSK Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs LUPIN - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA LUPIN GSK PHARMA/
LUPIN
 
P/E (TTM) x 31.7 105.7 30.0% View Chart
P/BV x 12.6 2.4 526.3% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 GSK PHARMA   LUPIN
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
LUPIN
Mar-19
GSK PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs3,595986 364.6%   
Low Rs1,253720 173.9%   
Sales per share (Unadj.) Rs184.7369.5 50.0%  
Earnings per share (Unadj.) Rs26.313.4 196.1%  
Cash flow per share (Unadj.) Rs29.237.4 78.0%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs126.3303.7 41.6%  
Shares outstanding (eoy) m169.40452.49 37.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x13.12.3 568.4%   
Avg P/E ratio x92.263.6 144.8%  
P/CF ratio (eoy) x83.122.8 364.2%  
Price / Book Value ratio x19.22.8 683.1%  
Dividend payout %76.10-   
Avg Mkt Cap Rs m410,626386,064 106.4%   
No. of employees `0005.017.7 28.0%   
Total wages/salary Rs m5,37231,513 17.0%   
Avg. sales/employee Rs Th6,306.79,453.8 66.7%   
Avg. wages/employee Rs Th1,083.11,782.0 60.8%   
Avg. net profit/employee Rs Th898.0343.0 261.8%   
INCOME DATA
Net Sales Rs m31,281167,182 18.7%  
Other income Rs m1,0233,640 28.1%   
Total revenues Rs m32,304170,822 18.9%   
Gross profit Rs m6,00928,822 20.8%  
Depreciation Rs m48610,850 4.5%   
Interest Rs m63,078 0.2%   
Profit before tax Rs m6,54018,534 35.3%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m287-3,400 -8.4%   
Tax Rs m2,3739,017 26.3%   
Profit after tax Rs m4,4546,066 73.4%  
Gross profit margin %19.217.2 111.4%  
Effective tax rate %36.348.7 74.6%   
Net profit margin %14.23.6 392.5%  
BALANCE SHEET DATA
Current assets Rs m20,061138,536 14.5%   
Current liabilities Rs m14,54361,299 23.7%   
Net working cap to sales %17.646.2 38.2%  
Current ratio x1.42.3 61.0%  
Inventory Days Days5784 67.8%  
Debtors Days Days14112 12.5%  
Net fixed assets Rs m14,343127,516 11.2%   
Share capital Rs m1,694905 187.2%   
"Free" reserves Rs m19,704136,517 14.4%   
Net worth Rs m21,398137,422 15.6%   
Long term debt Rs m266,417 0.0%   
Total assets Rs m39,113279,494 14.0%  
Interest coverage x1,091.07.0 15,539.4%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.80.6 133.7%   
Return on assets %11.43.3 348.5%  
Return on equity %20.84.4 471.6%  
Return on capital %31.98.9 358.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53459,414 0.9%   
Fx outflow Rs m7,09122,282 31.8%   
Net fx Rs m-6,55737,132 -17.7%   
CASH FLOW
From Operations Rs m3,99416,660 24.0%  
From Investments Rs m-1,433-32,825 4.4%  
From Financial Activity Rs m-3,5847,441 -48.2%  
Net Cashflow Rs m-1,023-8,724 11.7%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 50.7 0.2 25,350.0%  
Indian inst/Mut Fund % 10.2 11.3 90.3%  
FIIs % 23.8 31.9 74.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.1 152.5%  
Shareholders   102,036 98,259 103.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 229 Points Lower; Banking and Metal Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today amid weak global cues and disappointing domestic factory output data.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS